TITLE

Determination That PITRESSIN TANNATE IN OIL (Vasopressin Tannate) Injection, 5 Pressor Units/ Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AUTHOR(S)
Kux, Leslie
PUB. DATE
May 2012
SOURCE
Federal Register (National Archives & Records Service, Office of;5/18/2012, Vol. 77 Issue 97, p29665
SOURCE TYPE
Government Documents
DOC. TYPE
Article
ABSTRACT
The article presents information on a notice issued by the U.S Food and Drug Administration (FDA) regarding the determination of withdrawal of pitressin tannate in oil injection from sale for reasons of safety or effectiveness. It discusses the importance of this determination in allowing FDA to approve abbreviated new drug applications for vasopressin tannate injection, 5 pressor units/milli litres.
ACCESSION #
76112091

 

Related Articles

  • Compounding Pharmacies Or Big Drugmakers? Sorscher, Sarah // Public Citizen News;Nov/Dec2013, Vol. 33 Issue 6, p8 

    The article discusses the sickening of around 700 patients by contaminated steroid injections in the fall of 2012, which was distributed by the New England Compounding Pharmacy Inc. located in Massachusetts. Topics discussed include death of 60 people since the outbreak and suffering of many...

  • Tolvaptan. Ghali, Jalal K.; Hamad, Bashar; Yasothan, Uma; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Aug2009, Vol. 8 Issue 8, p611 

    In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V2 receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.

  • FDA approves oral vasopressin antagonist. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;7/1/2009, Vol. 66 Issue 13, p1154 

    The article reports on the Food and Drug Administration approval of Tolvaptan, an oral vasopressin antagonist for the treatment of hyponatremia. It states that such medication administration requires health professionals' close monitoring of the patient in a hospital. Also mentioned are the...

  • FDA Drug Approvals.  // Formulary;Mar2005, Vol. 40 Issue 3, p74 

    This article presents information on drugs that are being approved by U.S. FDA. It is informed that a Clarithromycin extended-release tablet of 1,000mg has been approved by the FDA. The drug is being brought out by Ranbaxy Pharmaceuticals Inc. The FDA also approved Levofloxacin tablets of 750 mg...

  • Vasopressin receptor antagonists. Greenberg, A.; Verbalis, J. G. // Kidney International;Jun2006, Vol. 69 Issue 12, p2124 

    The first non-peptide vasopressin receptor antagonist (VRA) was recently approved by the United States Food and Drug Administration, and several others are now in late stages of clinical development. Phase 3 trials indicate that these agents predictably reduce urine osmolality, increase...

  • CRDAC Not Impressed, Votes No to Cornerstone' Lixivaptan. Serebrov, Mari // BioWorld Today;9/14/2012, Vol. 23 Issue 179, p2 

    The article reports on the decision of the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) to not recommend the approval of Cornerstone Therapeutics Inc.'s lixivaptan for hyponatremia. The decision was due to the drug's association with...

  • Samsca.  // Formulary;Jul2009, Vol. 44 Issue 7, p194 

    The article presents information on the drug Samsca (Tolvaptan), manufactured by Otsuka Pharmaceutical Co. Ltd., and approved by the U.S. Food and Drug Administration on May 19, 2009, for the treatment of patients with hypervolemic and euvoiemic hyponatremia. Tolvaptan is an oral selective...

  • Finally an Oral V2 Selective Vasopressin Antagonist. Anaizi, Nasr // Ibnosina Journal of Medicine & Biomedical Sciences;Dec2009, Vol. 1 Issue 3, p110 

    The article discusses the critical role of conivaptan, an oral non-peptide antagonist of selective arginine vasopressin (AVP) receptor subtypes V1 and V12, in renal hemodynamics and in the maintenance of water balance in hospitalized euvolemic and hypervolemic hyponatremic patients in the U.S....

  • Prescription ads next on FDA list. Colford, S.W. // Advertising Age;8/26/91, Vol. 62 Issue 35, p32 

    Examines Food & Drug Administration (FDA) plans to tighten regulations on drug advertising and various promotional practices. Principal concerns of Commissioner David Kessler; Present regulations of consumer ads for prescription drugs.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics